The direct-acting, potent, fast-acting P2Y12 inhibitor ticagrelor is recommended for the management of moderateto high-risk patients with acute coronary syndrome (ACS). 1, 2 Ticagrelor showed superior efficacy compared with clopidogrel in reducing cardiovascular events and mortality in the Platelet Inhibition and Patient Outcomes (PLATO) study, at the expense of an increase in major bleeding not related to coronary artery bypass graft (CABG) surgery. 3 However, generalization of results to individual regions or specific subgroups is challenging given the diversity of patients enrolled in this multinational trial.
Asian patients are believed to be susceptible to antithrombotics or fibrinolytics 4, 5 and to be associated with a higher bleeding risk during management of ischemic heart diseases and antithrombotic therapy. 6, 7 There are concerns about excessive bleeding risk with standard doses of new P2Y12 inhibitors in Asian patients, especially in East Asian countries. 8 For prasugrel, a lower maintenance dose of 3.75 mg daily was used in clinical studies and approved for Japanese patients. 9, 10 The lower body weight of Asian patients, fixed dose regimen of most antiplatelet drugs, and different genetic backgrounds may explain the potential for this increased bleeding risk. Thus, bleeding is viewed as a primary concern for selecting antiplatelet drugs in Asian patients. A clinical pharmacology study identified higher drug exposure in Japanese compared with white subjects participating in a study of single dose and multiple ascending doses of ticagrelor, adding weight to the general concern about bleeding in Asian patients. 11 However, to date, clinical outcomes data have been only modest; in addition, Asian patients with ACS may have different demographics, comorbidities, and disease patterns compared with white patients with ACS. 7, 12 Accordingly, we evaluated the association of race and antiplatelet drugs (ticagrelor vs clopidogrel) with efficacy and safety outcomes in a retrospective analysis of PLATO data. Specifically, our goal was to examine the effects of ticagrelor versus clopidogrel among Asians and non-Asians on cardiovascular events, net clinical benefit, and safety outcomes including bleeding.
Methods

Patients
PLATO was a multinational, multicenter, double-blind, double-dummy, randomized trial of 18,624 patients with ST-segment elevation or non-ST-segment elevation ACS. Details of the study design have been published previously. 3, 13 Briefly, patients were randomized to treatment with clopidogrel or ticagrelor after admission and within 24 hours of the acute event. Ticagrelor was administered as a 180-mg loading dose and then as 90 mg twice daily. Clopidogrel was administered with 75 mg once daily after a 300-mg loading dose. The loading dose of clopidogrel was used only for patients who had not been receiving clopidogrel for at least 5 days before randomization.
Asian race was investigator identified in the case report form. Asian race also included races specified as Filipino, Malay, Bidayuh, or mixed (white and Asian) among "other races" in the case report form. All remaining patients were considered to be non-Asian. Patients who lacked sufficient data for classification as Asian or non-Asian were excluded from this analysis. Asian patients from Asian regions were subclassified to East Asian (South Korea, China, or Hong Kong) and Southeast Asian countries (Thailand, Indonesia, Malaysia, Singapore, or Philippines) by regional location.
Main outcome measures
The key end points for this analysis were the primary efficacy outcome and net clinical benefit. The primary efficacy end point was the composite of death from vascular causes, myocardial infarction (MI), or stroke. Secondary efficacy end-points were all-cause death, death from vascular causes, the composite of vascular death or MI, stroke, and stent thrombosis defined as probable or definite by the Academic Research Consortium definition.
14 Net clinical benefit was defined as the composite of death from vascular causes, MI, stroke, or CABG or non-CABG-related major bleeding, which incorporated major bleeding into a major cardiovascular event for evaluation as a single outcome measure. The safety end points consisted of bleeding (PLATO-defined major bleeding, non-CABGrelated major bleeding, and fatal bleeding 13 ) and other safety end points (bradycardia and dyspnea).
Efficacy and net clinical benefit end points were analyzed based on the intent-to-treat paradigm through 12 months. Bleeding end points were evaluated as treated and included events that occurred during use of the study drug or within 7 days after treatment end.
Statistical analyses
Baseline characteristics were presented as medians (with 25th, 75th percentiles) for continuous variables and frequencies for categorical variables. Comparisons for baseline characteristics were made with a t test or Wilcoxon rank sum test for continuous variables, and a χ 2 or Fisher exact test for categorical variables. Cox proportional hazards regression assessed outcomes by race (Asian vs non-Asian). Furthermore, the interaction between race (Asian vs non-Asian) and antiplatelet treatment (ticagrelor vs clopidogrel) was assessed using Cox proportional hazards regression to evaluate whether a differential treatment effect existed by race.
Among the subgroup of patients living in the Asian region, we assessed outcomes by subregion (Southeast Asia vs East Asia) and further evaluated whether a differential treatment effect existed for Southeast Asian versus East Asian patients using methods similar to those described earlier. All analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC) and P b .05 was considered significant.
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Results
Baseline characteristics for Asian and non-Asian patients
Of the 18,621 patients included in this analysis from PLATO, 1,106 patients (5.9%) were reported as being Asian. There were significant differences in baseline characteristics between Asian and non-Asian patients (Table I, online  Appendix Supplementary Table) . Asian patients were slightly but significantly younger and had lower body weight and body mass index than non-Asian patients. Cardiovascular risk factors were also different between the 2 groups. Although current smoking status and diabetes mellitus were more common in Asian patients, hypertension and dyslipidemia were more common in non-Asian patients. Asian patients less commonly reported a previous MI or coronary revascularization, but a history of nonhemorrhagic stroke was more common in Asian patients. At the time of randomization, the most common type of ACS event in Asian patients was ST-segment elevation MI, whereas non-ST-segment elevation MI was more common in non-Asian patients. Concomitant medication was also significantly different between the 2 groups. In Asian patients, a lower proportion was treated with aspirin, β-blocker, statin, and glycoprotein IIb/IIIa inhibitor at baseline. A higher proportion of Asian patients than non-Asian patients had a planned invasive strategy.
Outcomes in Asian versus non-Asian patients
Increased risk of the net clinical benefit end point (hazard ratio [HR] 1.19, 95% CI 1.04-1.37, P = .013) and primary efficacy end point (HR 1.34, 95% CI 1.13-1.59, P = .001) was observed for the Asian patients compared with non-Asian. Similar results were observed for other efficacy end points including stroke and all-cause death. However, Asian origin was not associated with increased risk of PLATO major bleeding, non-CABG-related major bleeding, or fatal bleeding (P = .655, P = .467, and P = .355, respectively) (online Appendix Supplementary Table) . Among patients meeting the net clinical benefit end point because of major bleeding under the intent-to-treat paradigm, 12.8% (161/1,255) of non-Asian and 26.1% (23/88) of Asian patients subsequently also had a cardiovascular event (death from vascular cause, MI, or stroke) during the follow-up period.
Interaction of race and treatment
Figure and Table II show the relationship between treatment and outcomes by racial group. The reduced risk of primary efficacy end point was consistent between Asian and non-Asian patients (interaction P = .974). The benefits of ticagrelor compared with clopidogrel were consistent with net clinical benefit end point, incorporating major cardiovascular events and major bleeding, between the 2 racial groups (interaction P = .521). Similarly, we did not observe a differential treatment effect for secondary efficacy end points including all-cause death (P = .931), death from vascular causes (P = .792), composite of MI or vascular death (P = .972), stroke (P = .701), or stent thrombosis (P = .638). (See Table III .) Figure also shows that, compared with clopidogrel, the effect of ticagrelor on the primary safety end point, major bleeding, was not significantly different between Asian and non-Asian patients (interaction P = .938). Similar results were observed for non-CABG-related bleeding and adverse events including dyspnea and bradycardia (interaction P = .947, P = .894, and P = .856, respectively).
Discussion
In the PLATO study, the primary efficacy end point and net clinical benefits favored ticagrelor compared with clopidogrel. 3, 15 In the present subgroup analysis, the net clinical benefits of ticagrelor compared with clopidogrel were not different between Asian and non-Asian patients, although there were differences in baseline characteristics and cardiovascular event rates between the Asian and non-Asian. Similarly, there was no significant heterogeneity in effects of ticagrelor compared with clopidogrel on efficacy, bleeding, and other safety end points. The overall net clinical benefit of ticagrelor was primarily the result of reduced cardiovascular events, exceeding the observed increase of major bleeding in both Asian and non-Asian patients.
Concerns about increased susceptibility of bleeding in Asian patients compared with non-Asian patients are supported by lower body weight, differences in genetic background, comorbidities, and disease patterns of Asian patients compared with white patients as well as the use of single fixed-dose regimens in most antiplatelet and antithrombotic drugs. 7 However, data for bleeding risk by racial difference are limited, and the bleeding risk in Asian patients is inconsistent among studies. 7, 12, 16 Compared with clopidogrel, ticagrelor has a direct, potent, fast-acting P2Y12 inhibition in patients with coronary artery disease. 17, 18 Clinical pharmacology studies have reported higher drug exposure of ticagrelor in Japanese and Chinese patients and higher levels of inhibition for platelet aggregation in Japanese patients compared with whites. 11, 19 Nevertheless, the effects on bleeding outcomes defined as PLATO major bleeding, or non-CABG major bleeding for ticagrelor versus clopidogrel did not differ between Asian patients and non-Asian patients in the present study. Although greater platelet inhibition was associated with higher bleeding risk, the relationship between level of platelet inhibition and bleeding risk is not straightforward, 15, 20 and it has not been established how to estimate risk of major bleeding by level of platelet inhibition. 15, 20, 21 As shown with race, increased drug exposure of ticagrelor has been reported for elderly patients and female patients in clinical pharmacology studies. 11 However, risk of PLATO major bleeding has not been significantly different according to gender and age in comparisons of ticagrelor and clopidogrel. 3, 15 Different genetic predisposition needs to be considered for evaluation of antiplatelet therapy when clopidogrel is used as a control. Loss of function alleles of cytochrome P450 2C19 (CYP2C19) is more common in the Asian population compared with the non-Asian population 22 and is associated with a lower level of platelet inhibition and an increased risk of ischemic events in clopidogrel Data are presented as n (%). Primary efficacy end point is a composite of death from vascular causes, MI, or stroke. users. 23, 24 Unlike clopidogrel, ticagrelor is not influenced by CYP2C19 polymorphism. 25 The higher prevalence of loss of CYP2C19 function polymorphism in Asian patients may favor ticagrelor compared with clopidogrel in terms of platelet inhibition and may be related to the observed reduction in ischemic events. However, in terms of bleeding risk, presence of CYP2C19 loss of function alleles may be associated with a reduced risk of bleeding events in patients treated with clopidogrel. 6, 25 Bleeding is known to be associated with increased risk of cardiovascular events. 26 In the present analysis, a higher cardiovascular event rate was observed in both Asian and non-Asian patients who experienced major bleeding compared with patients without bleeding. However, susceptibility of subsequent cardiovascular event after major bleeding might be different between Asian and non-Asian patients. Numerically higher subsequent ischemic events were observed in Asian patients who experienced major bleeding than in those without bleeding. This finding needs further evaluation and confirmation in future studies. The reason why Asian patients were more susceptible to subsequent cardiovascular events after a major bleeding is unclear. The risk factors associated with major bleeding may have a greater association with risk factors of cardiovascular event, or differences in practice patterns, or comorbidities may influence the subsequent cardiovascular events. The preconceived idea that Asian patients are prone to higher risk of bleeding may result in more frequent discontinuation of study drugs or antithrombotic drugs in Asian patients. In the context of frequent use of percutaneous coronary intervention in high-risk patients with ACS, outcomes of premature or inappropriate discontinuation of antithrombotic drug could be detrimental.
This study was limited in that it was a retrospective analysis of the PLATO study. There was a relatively modest number of Asian patients included in our analysis, and the population was heterogeneous. Defining Asian patients is difficult for many reasons. To minimize the extent of heterogeneity, we prespecified exclusion of patients from the Indian subcontinent. Accordingly, our study population best reflects patients from East and Southeast Asia. Nevertheless, to the best of our knowledge, this represents the largest study cohort to date of Asian patients receiving ticagrelor in the setting of ACS.
There were significant differences in demographics, risk factors, comorbidities, disease pattern, and use of treatments between Asian and non-Asian patients. Nevertheless, the effects of ticagrelor compared with clopidogrel on net clinical benefit, ischemic events, bleeding, and adverse reactions were consistent in Asian patients compared with non-Asian patients in this analysis. In Asian patients, risk of major bleeding associated with ticagrelor compared with clopidogrel did not exceed the benefits from reduction in cardiovascular events in this analysis. Except where indicated, data are presented as n (%). Abbreviations: MI, Myocardial infarction PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TIA, transient ischemic attack; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin II receptor blocker. ⁎ Presented as median value with first and third quartiles.
